REGENXBIO (RGNX) Stock Analysis & Winston Score

REGENXBIO is a biotechnology company that develops gene therapies — treatments that try to fix diseases by delivering corrected genetic instructions into a patient's cells. Its main technology platform is called NAV, a collection of engineered viruses (called AAV vectors) used to carry genes into the body. The company focuses on serious diseases with few or no existing treatments, including eye diseases, neurological conditions, and metabolic disorders. REGENXBIO makes money in two ways: licensing its NAV technology to other biotech and pharmaceutical companies, and developing its own pipeline of gene therapy drugs. It operates primarily in the United States and is a small-cap company with a market cap around $600 million. The licensing business provides some recurring revenue, but the company is spending far more than it earns, reflected in its deeply negative operating margin. Its biggest risk is whether its internally developed therapies can successfully complete clinical trials and win regulatory approval before its cash runs out.